Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Withey SL, Paronis CA, Bergman J.

J Pain. 2018 Jul;19(7):728-740. doi: 10.1016/j.jpain.2018.02.003. Epub 2018 Mar 2.

PMID:
29477761
2.

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Paronis CA, Chopda GR, Vemuri K, Zakarian AS, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2018 Mar;364(3):485-493. doi: 10.1124/jpet.117.245647. Epub 2018 Jan 8.

PMID:
29311110
3.

Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.

Kulkarni S, Nikas SP, Sharma R, Jiang S, Paronis CA, Leonard MZ, Zhang B, Honrao C, Mallipeddi S, Raghav JG, Benchama O, Järbe TU, Bergman J, Makriyannis A.

J Med Chem. 2016 Jul 28;59(14):6903-19. doi: 10.1021/acs.jmedchem.6b00717. Epub 2016 Jul 13.

4.

Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.

Chopda GR, Parge V, Thakur GA, Gatley SJ, Makriyannis A, Paronis CA.

J Pharmacol Exp Ther. 2016 Aug;358(2):334-41. doi: 10.1124/jpet.116.232132. Epub 2016 May 26.

5.

Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols.

Nikas SP, Sharma R, Paronis CA, Kulkarni S, Thakur GA, Hurst D, Wood JT, Gifford RS, Rajarshi G, Liu Y, Raghav JG, Guo JJ, Järbe TU, Reggio PH, Bergman J, Makriyannis A.

J Med Chem. 2015 Jan 22;58(2):665-81. doi: 10.1021/jm501165d. Epub 2014 Dec 16.

6.

Effects of the δ opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse.

Hudzik TJ, Pietras MR, Caccese R, Bui KH, Yocca F, Paronis CA, Swedberg MD.

Pharmacol Biochem Behav. 2014 Sep;124:48-57. doi: 10.1016/j.pbb.2014.05.009. Epub 2014 May 22.

PMID:
24857840
7.

Controlled-deactivation cannabinergic ligands.

Sharma R, Nikas SP, Paronis CA, Wood JT, Halikhedkar A, Guo JJ, Thakur GA, Kulkarni S, Benchama O, Raghav JG, Gifford RS, Järbe TU, Bergman J, Makriyannis A.

J Med Chem. 2013 Dec 27;56(24):10142-57. doi: 10.1021/jm4016075. Epub 2013 Dec 10.

8.

Diuretic effects of cannabinoid agonists in mice.

Chopda GR, Vemuri VK, Sharma R, Thakur GA, Makriyannis A, Paronis CA.

Eur J Pharmacol. 2013 Dec 5;721(1-3):64-9. doi: 10.1016/j.ejphar.2013.09.053. Epub 2013 Oct 5.

9.

Ethanol self-administration in rats responding under concurrent schedules for milk or ethanol plus milk.

Paronis CA.

Behav Pharmacol. 2013 Sep;24(5-6):486-95. doi: 10.1097/FBP.0b013e328364c006.

PMID:
23903243
10.

Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Paronis CA, Nikas SP, Shukla VG, Makriyannis A.

Behav Pharmacol. 2012 Dec;23(8):802-5. doi: 10.1097/FBP.0b013e32835a7c4d.

11.

Diuretic effects of cannabinoids.

Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, Bergman J.

J Pharmacol Exp Ther. 2013 Jan;344(1):8-14. doi: 10.1124/jpet.112.199331. Epub 2012 Sep 27.

12.

Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Paronis CA, Bergman J.

J Pharmacol Exp Ther. 2011 Feb;336(2):488-95. doi: 10.1124/jpet.110.173823. Epub 2010 Nov 4.

13.

Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.

Nikas SP, Alapafuja SO, Papanastasiou I, Paronis CA, Shukla VG, Papahatjis DP, Bowman AL, Halikhedkar A, Han X, Makriyannis A.

J Med Chem. 2010 Oct 14;53(19):6996-7010. doi: 10.1021/jm100641g.

14.

Monoaminergic psychomotor stimulants: discriminative stimulus effects and dopamine efflux.

Desai RI, Paronis CA, Martin J, Desai R, Bergman J.

J Pharmacol Exp Ther. 2010 Jun;333(3):834-43. doi: 10.1124/jpet.110.165746. Epub 2010 Feb 26.

15.

Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A.

Physiol Behav. 2008 Mar 18;93(4-5):666-70. Epub 2007 Nov 12. Review.

16.

Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats.

Desai RI, Neumeyer JL, Bergman J, Paronis CA.

Behav Pharmacol. 2007 Dec;18(8):745-54.

PMID:
17989512
17.

Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys.

Delatte MS, Paronis CA.

Psychopharmacology (Berl). 2008 Jul;198(4):521-8. Epub 2007 Sep 19.

PMID:
17882403
18.

Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys.

Desai RI, Neumeyer JL, Paronis CA, Nguyen P, Bergman J.

Eur J Pharmacol. 2007 Mar 8;558(1-3):98-106. Epub 2006 Dec 1. Erratum in: Eur J Pharmacol. 2007 Dec 1;575(1-3):187.

19.

Measuring the reinforcing strength of abused drugs.

Bergman J, Paronis CA.

Mol Interv. 2006 Oct;6(5):273-83. Review.

PMID:
17035668
20.

Modulating GABA modulators.

Paronis CA.

Br J Pharmacol. 2006 Feb;147(3):237-8.

21.
22.

Modification by dopaminergic drugs of choice behavior under concurrent schedules of intravenous saline and food delivery in monkeys.

Gasior M, Paronis CA, Bergman J.

J Pharmacol Exp Ther. 2004 Jan;308(1):249-59. Epub 2003 Oct 16.

23.

Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking.

Kassel JD, Stroud LR, Paronis CA.

Psychol Bull. 2003 Mar;129(2):270-304. Review.

PMID:
12696841
24.

Effects of cocaine under concurrent fixed ratio schedules of food and IV drug availability: a novel choice procedure in monkeys.

Paronis CA, Gasior M, Bergman J.

Psychopharmacology (Berl). 2002 Oct;163(3-4):283-91. Epub 2002 Jul 30.

PMID:
12373429
25.
26.

Acute dependence on, but not tolerance to, heroin and morphine as measured by respiratory effects in rhesus monkeys.

Kishioka S, Paronis CA, Woods JH.

Eur J Pharmacol. 2000 Jun 9;398(1):121-30.

PMID:
10856456
27.

Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys.

Kishioka S, Paronis CA, Lewis JW, Woods JH.

Eur J Pharmacol. 2000 Mar 17;391(3):289-97.

PMID:
10729371
28.

Apparent pA2 values of benzodiazepine antagonists and partial agonists in monkeys.

Paronis CA, Bergman J.

J Pharmacol Exp Ther. 1999 Sep;290(3):1222-9.

29.

Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.

Paronis CA, Woods JH.

Eur J Pharmacol. 1997 Oct 15;337(1):27-34.

PMID:
9389377
31.
32.

Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists.

Paronis CA, Holtzman SG.

Psychopharmacology (Berl). 1994 May;114(4):601-10.

33.
34.
35.
36.

Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.

Paronis CA, Holtzman SG.

J Pharmacol Exp Ther. 1991 Nov;259(2):582-9.

PMID:
1658305
37.

Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine.

Adams JU, Paronis CA, Holtzman SG.

J Pharmacol Exp Ther. 1990 Dec;255(3):1027-32.

PMID:
2175793

Supplemental Content

Loading ...
Support Center